Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure: A Randomized Trial

RCT (n=1222) found for every 100 days of follow-up, patients on SGLT2-inhibitor, sotagliflozin, were alive and out of hospital for 3% or 2.9 more days than those on placebo (91.8 vs. 88.9 days); reflecting 2.6-day difference in days dead and 0.3-day difference in days in hospital

SPS commentary:

Sotaglifozin is approved in EU as adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes and a body mass index ≥27 kg/m2, who could not achieve adequate glycaemic control despite optimal insulin therapy. It has not been launched in UK as yet.

Annals of Internal Medicine